Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02797782|
Recruitment Status : Recruiting
First Posted : June 13, 2016
Last Update Posted : June 20, 2017
More than two billion individuals have serological evidence of hepatitis B virus (HBV) infection worldwide. Of these, 240 million are chronic carriers and approximately 786,000 hepatitis B related deaths occur annually.
Currently available hepatitis B vaccines are extremely safe and have an efficacy of >90 percent against all HBV serotypes and genotypes. Thus, HBV infection can potentially be eradicated through global vaccination. A positive immune response to the vaccine is defined as the development of hepatitis B surface antibody (anti-HBs) at a titer of >10 mIU/mL.
Although anti-HBs titers decrease with time, the duration of protection is long. Protection has been estimated to persist for up to 22 years after the primary vaccination schedule. Protection from clinical disease, despite declining or even undetectable anti-HBs levels, is probably due to the priming of memory cells, which are capable of eliciting an anamnestic response when challenged. This is supported by the rapid increases in anti-HBs titers in previously vaccinated individuals who administered booster injections.
|Condition or disease||Intervention/treatment|
|Hepatitis B Vaccines||Other: Detection of anti HBs antibody titer|
A significant proportion of the vaccinated population loses both the protective levels of anti-HBs and an anamnestic response. Recommendations for booster vaccination have been proposed in a European consensus statement. Countries like the Netherlands, Germany, Spain, France and Belgium recommend a booster dose depending on the post-vaccination anti-HBs titer. In the UK, a single booster dose is recommended five years after primary vaccination.
In Egypt, the routine infant immunization for hepatitis B virus started in 1992, and was given at 2nd, 4th and 6th months of age. In the present study the investigators will investigate the long term efficacy of hepatitis B vaccination in young adults 20 to 22 years after the primary vaccination in Nile Delta of Egypt.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Young Adults 20-22 Years After the Primary Vaccination in Nile Delta of Egypt|
|Study Start Date :||June 2016|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||March 2019|
Other: Detection of anti HBs antibody titer
- Number of individuals with protective anti-HBs antibody titers [ Time Frame: 1 year ]Number of individuals having protective anti-HBs antibody titers
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02797782
|Contact: Sherief Abd-Elsalam, Consultantfirstname.lastname@example.org|
|Contact: Sherief Abd-elsalam, lecturer 00201000040794 Sherif_tropical@yahoo.com|
|Principal Investigator:||Asem Elfert, Prof||Hepatology and gastroenterology dept.-Tanta|
|Study Chair:||Reham Elkhouly, Consultant||Division of Gastroenterology and Hepatology- Tanta|
|Study Chair:||Rehab Badawi, Consultant||Hepatology and gastroenterology dept.-Tanta|
|Study Chair:||Walaa Elkhalawany, Consultant||Hepatology and gastroenterology dept.-Tanta|
|Study Chair:||Mona Watany, Consultant||clinical pathology dept.-Tanta|
|Study Chair:||Sherief Abd-Elsalam, Consultant||Hepatology and gastroenterology dept.-Tanta|